These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26754796)

  • 1. Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women.
    Urano T; Shiraki M; Kuroda T; Tanaka S; Uenishi K; Inoue S
    J Bone Miner Metab; 2017 Jan; 35(1):108-113. PubMed ID: 26754796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.
    Urano T; Shiraki M; Kuroda T; Tanaka S; Urano F; Uenishi K; Inoue S
    J Bone Miner Metab; 2018 Nov; 36(6):734-740. PubMed ID: 29236162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.
    Sarkar S; Reginster JY; Crans GG; Diez-Perez A; Pinette KV; Delmas PD
    J Bone Miner Res; 2004 Mar; 19(3):394-401. PubMed ID: 15040827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of bone mass by estrogens and raloxifene during exercise-induced weight Loss.
    Gozansky WS; Van Pelt RE; Jankowski CM; Schwartz RS; Kohrt WM
    J Clin Endocrinol Metab; 2005 Jan; 90(1):52-9. PubMed ID: 15494466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of low bone mass in postmenopausal Kuwaiti women residents in the largest province of Kuwait.
    Al-Shoumer KA; Nair V
    Arch Osteoporos; 2012; 7():147-53. PubMed ID: 23225292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aged-Related Changes in Body Composition and Association between Body Composition with Bone Mass Density by Body Mass Index in Chinese Han Men over 50-year-old.
    Jiang Y; Zhang Y; Jin M; Gu Z; Pei Y; Meng P
    PLoS One; 2015; 10(6):e0130400. PubMed ID: 26090818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between body composition and age, menopause and its effects on bone mineral density at segmental regions in Central Southern Chinese postmenopausal elderly women with and without osteoporosis.
    Liu S; Li J; Sheng Z; Wu X; Liao E
    Arch Gerontol Geriatr; 2011; 53(2):e192-7. PubMed ID: 20880598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
    Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
    Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
    Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
    Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
    J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
    Khedr NF; El-Ashmawy NE; El-Bahrawy HA; Haggag AA; El-Abd EE
    Fundam Clin Pharmacol; 2013 Oct; 27(5):526-34. PubMed ID: 22762129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes.
    Mori H; Okada Y; Kishikawa H; Inokuchi N; Sugimoto H; Tanaka Y
    J Bone Miner Metab; 2013 Jan; 31(1):89-95. PubMed ID: 22868657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.